Philippe Camus, M.D.

Dijon, France

Back

The Drug-Induced Respiratory Disease Website

Adalimumab

II - Myocardial dysfunction - Heart failure

II.c

Heart failure (biventricular, congestive)

XII - Pericardial involvement

XII.g

Pleural/pericardial effusion, ANA positive (DI lupus)
XII.n

Pleuropericarditis - Pleuropericardial effusion (ANA unknown or negative)

XVI - Hemorrhage - Bleeding - Hematoma(s)

XVI.e

Alveolar hemorrhage (AH), diffuse AH (DAH)
XVI.g

Alveolar hemorrhage, diffuse (ANCA-positive/-related)

XXII - Acute respiratory/cardiorespiratory failure

XXII.b

Acute lung injury - ARDS

XXIV - Interstitial lung disease - Pulmonary infiltrates - Pulmonary fibrosis

XXIV.a

Pneumonitis (ILD)
XXIV.b

Pneumonitis (ILD), acute and/or severe (may cause ARDS)
XXIV.c

Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)
XXIV.h

Pulmonary fibrosis (may improve but partly following drug discontinuation)
XXIV.j

Organizing pneumonia (OP/BOOP) pattern (an area or areas of consolidation on imaging)

XXVI - Neuromuscular dysfunction

XXVI.a

Phrenic nerve injury - Hemi- or bilateral diaphragmatic paralysis

XXIX - Small airway involvement

XXIX.a

Bronchospasm - Wheezing - Asthma

XXXVI - Autoimmune syndromes - Systemic reactions or conditions

XXXVI.a

Autoimmunity - An autoimmune condition (+ANA, +anti-ds-DNA, +ANCAs, other auto-Abs)
XXXVI.b

Lupus - Lupus syndrome

XXXVIII - Miscellaneous - Varia

XXXVIII.c

Antiphospholipid antibodies w/wo the APL syndrome
XXXVIII.q

Myopathy-Myositis-Polymyositis